Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Assets (2022 - 2025)

Historic Current Assets for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $300.0 million.

  • Taysha Gene Therapies' Current Assets rose 8566.49% to $300.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.0 million, marking a year-over-year increase of 8566.49%. This contributed to the annual value of $142.1 million for FY2024, which is 516.32% down from last year.
  • Taysha Gene Therapies' Current Assets amounted to $300.0 million in Q3 2025, which was up 8566.49% from $316.3 million recorded in Q2 2025.
  • Taysha Gene Therapies' Current Assets' 5-year high stood at $316.3 million during Q2 2025, with a 5-year trough of $43.0 million in Q3 2022.
  • In the last 4 years, Taysha Gene Therapies' Current Assets had a median value of $130.6 million in 2024 and averaged $141.4 million.
  • Within the past 5 years, the most significant YoY rise in Taysha Gene Therapies' Current Assets was 29953.26% (2023), while the steepest drop was 3230.67% (2023).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Current Assets stood at $96.4 million in 2022, then surged by 55.44% to $149.9 million in 2023, then fell by 5.16% to $142.1 million in 2024, then surged by 111.04% to $300.0 million in 2025.
  • Its Current Assets was $300.0 million in Q3 2025, compared to $316.3 million in Q2 2025 and $120.7 million in Q1 2025.